[go: up one dir, main page]

FI944546L - Enantiomeerinen 1-fenyyli-2-(2pyridinyyli)etyyliamiini neurodegeneratiivisten häiriöiden hoitoon - Google Patents

Enantiomeerinen 1-fenyyli-2-(2pyridinyyli)etyyliamiini neurodegeneratiivisten häiriöiden hoitoon Download PDF

Info

Publication number
FI944546L
FI944546L FI944546A FI944546A FI944546L FI 944546 L FI944546 L FI 944546L FI 944546 A FI944546 A FI 944546A FI 944546 A FI944546 A FI 944546A FI 944546 L FI944546 L FI 944546L
Authority
FI
Finland
Prior art keywords
enantiomeric
ethylamine
pyridinyl
phenyl
treatment
Prior art date
Application number
FI944546A
Other languages
English (en)
Swedish (sv)
Other versions
FI944546A0 (fi
FI105025B (fi
Inventor
Ronald Conrad Griffith
Robert John Murray
Michael Balestra
Original Assignee
Fisons Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Fisons Corp filed Critical Fisons Corp
Publication of FI944546A0 publication Critical patent/FI944546A0/fi
Publication of FI944546L publication Critical patent/FI944546L/fi
Application granted granted Critical
Publication of FI105025B publication Critical patent/FI105025B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
FI944546A 1992-04-03 1994-09-30 Menetelmä valmistaa (S)-alfa-fenyyli-2-pyridiinietaaniamiinia FI105025B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9207339 1992-04-03
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB9208290 1992-04-15
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties
GB9300689 1993-04-01
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders

Publications (3)

Publication Number Publication Date
FI944546A0 FI944546A0 (fi) 1994-09-30
FI944546L true FI944546L (fi) 1994-09-30
FI105025B FI105025B (fi) 2000-05-31

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944546A FI105025B (fi) 1992-04-03 1994-09-30 Menetelmä valmistaa (S)-alfa-fenyyli-2-pyridiinietaaniamiinia

Country Status (29)

Country Link
EP (1) EP0633879B1 (fi)
JP (2) JP3120810B2 (fi)
KR (1) KR100259567B1 (fi)
CN (1) CN1044367C (fi)
AT (1) ATE163925T1 (fi)
AU (2) AU3897693A (fi)
CA (1) CA2133427C (fi)
CZ (1) CZ288519B6 (fi)
DE (1) DE69317411T2 (fi)
DK (1) DK0633879T3 (fi)
DZ (1) DZ1677A1 (fi)
ES (1) ES2115055T3 (fi)
FI (1) FI105025B (fi)
HK (1) HK1009331A1 (fi)
HU (1) HU211529A9 (fi)
IL (1) IL105276A (fi)
MA (1) MA22866A1 (fi)
MX (1) MX9301935A (fi)
MY (1) MY110149A (fi)
NO (1) NO302170B1 (fi)
NZ (1) NZ251384A (fi)
PL (1) PL180014B1 (fi)
RU (1) RU2128650C1 (fi)
SG (1) SG47948A1 (fi)
SK (1) SK281258B6 (fi)
TW (1) TW282455B (fi)
UA (1) UA29437C2 (fi)
WO (1) WO1993020052A1 (fi)
ZA (1) ZA932415B (fi)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
EP0648489A1 (en) * 1988-08-12 1995-04-19 Fisons Corporation Arylalkylamides having neuroprotective properties
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
EP2610246A1 (en) * 2008-12-24 2013-07-03 AstraZeneca AB Ethanamine compounds and methods of using the same
EP2791352A1 (en) 2011-12-14 2014-10-22 Astrazeneca AB Gabr-a2 diagnostic
HUE045001T2 (hu) * 2013-11-05 2019-12-30 Astrazeneca Ab NMDA antagonista prodrugok
PH12022553502A1 (en) * 2020-06-23 2024-04-22 Biohaven Therapeutics Ltd Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648489A1 (en) * 1988-08-12 1995-04-19 Fisons Corporation Arylalkylamides having neuroprotective properties

Also Published As

Publication number Publication date
AU3897693A (en) 1993-11-08
WO1993020052A1 (en) 1993-10-14
SK281258B6 (sk) 2001-01-18
TW282455B (fi) 1996-08-01
FI944546A0 (fi) 1994-09-30
AU7545696A (en) 1997-02-13
KR100259567B1 (ko) 2000-07-01
DZ1677A1 (fr) 2002-02-17
CA2133427C (en) 2003-06-10
HK1009331A1 (en) 1999-05-28
UA29437C2 (uk) 2000-11-15
DE69317411T2 (de) 1998-07-30
CN1044367C (zh) 1999-07-28
SK117794A3 (en) 1995-05-10
EP0633879A1 (en) 1995-01-18
RU2128650C1 (ru) 1999-04-10
PL180014B1 (pl) 2000-11-30
NO302170B1 (no) 1998-02-02
NO943645L (no) 1994-11-16
ATE163925T1 (de) 1998-03-15
RU94042465A (ru) 1996-07-20
MA22866A1 (fr) 1993-12-31
DE69317411D1 (de) 1998-04-16
NZ251384A (en) 1996-10-28
MX9301935A (es) 1994-08-31
SG47948A1 (en) 1998-04-17
HU211529A9 (en) 1995-11-28
JP3120810B2 (ja) 2000-12-25
CZ288519B6 (cs) 2001-07-11
EP0633879B1 (en) 1998-03-11
JPH07505385A (ja) 1995-06-15
NO943645D0 (no) 1994-09-30
MY110149A (en) 1998-02-28
AU705419B2 (en) 1999-05-20
CN1081669A (zh) 1994-02-09
IL105276A0 (en) 1993-08-18
DK0633879T3 (da) 1998-09-28
IL105276A (en) 1997-06-10
FI105025B (fi) 2000-05-31
JP2000319259A (ja) 2000-11-21
ES2115055T3 (es) 1998-06-16
CZ240994A3 (en) 1995-12-13
ZA932415B (en) 1993-10-22
CA2133427A1 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
US5281607B1 (en) Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
FI933505L (fi) Foerfarande foer framstaellning av etenpolymerer med en reducerad halt avkomponenter som kan extraheras med hexan
NO965377L (no) Indolinonforbindelser for behandling av sykdommer
NO963785D0 (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
EP0673384A4 (en) POLYPEPTIDES USEFUL IN TREATING INFLAMMABLE DISEASES.
AU6222096A (en) Phenoxy piperazine derivatives for treating disorders of the dopamine system
FI944546L (fi) Enantiomeerinen 1-fenyyli-2-(2pyridinyyli)etyyliamiini neurodegeneratiivisten häiriöiden hoitoon
FI103033B1 (fi) Menetelmä titaanin talteenottamiseksi
IT9021645A0 (it) Procedimento per il trattamento di torbide di raffineria
NO974569L (no) Benzamider for behandling av neurodegenerative forstyrrelser
EE9700268A (et) Meetod ratseemilise ja enantiomeerse 1-(püridüül)-2-tsükloheksüületüülamiini valmistamiseks
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
DK632388D0 (da) Pharmaceutisk middel til behandling af hypolipidaemi hos pattedyr
DE68909304D1 (de) Aminosäuren für der Behandung neurodegenerativer Störungen.
NO943723D0 (no) Anvendelse av kinolin-3-karboksamidforbindelser for behandling av diabetes
FI943833A0 (fi) Menetelmä 2,3,5,6-tetraklooripyridiinin valmistamiseksi
FI952953A0 (fi) Aineita metabolisten luustosairauksien hoitamiseen
ITPD910141A1 (it) Procedimento perfezionato per la realizzazione di calzature
FR2688505B1 (fr) Nouveau procede de preparation de 4-pyrimidinones.
FI943660A0 (fi) Menetelmä 3-karbonyyliandrostadieeni-17-karboksamidien valmistamiseksi
KR970020846U (ko) 근골격계질환 치료보조용 반창고
FI941667A (fi) Menetelmä terapeuttisesti käyttökelpoisten trisubstituoitujen sykloalkaanijohdannaisten valmistamiseksi
KR960010871U (ko) 스티어링 휘일의 높이를 조절하기 위한 장치
KR950700748A (ko) 섬유증 질환의 치료방법(use of mannose phosphates for the treatment of fibrotic disorders)
ITMI921770A1 (it) Composizioni farmaceutiche atte al trattamento dei disturbi della memoria.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: ASTRA AB

MA Patent expired